Correlation between dietary inflammation and mortality among hyperlipidemics

Abstract

Background and objective Although the the Dietary Inflammatory Index (DII) serves to be one of the reliable indicator for hyperlipidaemia, there is still uncertainty about its relationship to prognosis in the hyperlipidaemic population. In current study, the DII levels were analyzed in relation to the mortality risk among among the hyperlipidaemic individuals with the aim of determining any prospective correlation. Methods 14,460 subjects with hyperlipidaemia from the 10-year (2001–2010) National Health and Nutrition Examination Survey (NHANES) were chosen for this study. The endpoint event for follow-up was all-cause mortality, and subjects were tracked for up to December 31, 2019, or death, whichever occurred first. The tertiles of the DII levels were utilized for categorizing the study population into three groups. Survival curves, Cox proportional hazards regression models, restricted cubic spline (RCS), subgroup and interaction analyses, and sensitivity analyses were employed sequentially for the purpose of evaluating the association of the DII with mortality. Results 3170 (21.92%) all-cause deaths were recorded during an average 148-month follow-up period. Kaplan-Meier survival curves indicated that the survival rate of participants divided into the low DII group was substantially improved compared to that of those in the higher DII group (log-rank P < 0.001). After controlling for confounders, higher levels of DII were observed to be meaningfully linked to an elevated risk of death, no matter whether DII was specified for the continuous (hazard ratio (HR): 1.06; 95% confidence interval (CI): 1.04–1.08) or the categorical variable (HR: 1.22; 95% CI: 1.11–1.33). The DII and mortality displayed a linear association, according to the RCS. Stratified and sensitivity analyses reinforced the proof that these findings were reliable. Conclusion Among patients with hyperlipidaemia, the risk of death was positively and linearly linked with DII levels.

Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017–2018

“…Hyperlipidemia is determined by assessing various parameters, including LDL-C levels of 130 mg/dL or higher (equivalent to 3.37 mmol/L or above), total cholesterol levels of 200 mg/dL or higher (5.18 mmol/L or above), TG levels of 150 mg/dL or higher (1.7 mmol/L or above), and HDL-C levels below 40 mg/dL for men (less than 1.04 mmol/L) or below 50 mg/dL for women (less than 1.30 mmol/L). Additionally, the use of lipid-lowering medications is also considered in the determination of hyperlipidemia ( 28 ). The laboratory test measures include HbA1c, fasting glucose, hs-CRP, fasting TG, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), HDL-C, ALT, AST, and HOMA-IR.…”